Data-Driven Decision-Making in Advanced Breast Cancer: HR+ Breast Cancer Updates

Expert perspectives on the evolving treatment landscape of HR+ breast cancer and how novel therapies have been incorporated in practice.

EP. 1: Best Practices for Molecular Testing in Early-Stage Breast Cancer

February 9th 2023

Expert panelists share their perspectives on best practices for molecular profiling in patients diagnosed with early-stage breast cancer.

EP. 2: How Ki67 Informs Use of Therapy in Early-Stage HR+ Breast Cancer

February 9th 2023

A broad look at the role of Ki67 expression in informing the selection of therapy for patients with early-stage HR+ breast cancer.

EP. 3: Early-Stage HR+ Breast Cancer: Ki67 and the monarchE Trial

February 16th 2023

Key opinion leaders in breast cancer management discuss Ki67 and the monarchE trial, which analyzed abemaciclib therapy in the HR+ space.

EP. 4: How Clinical Trials Inform Treatment Selection in Early-Stage HR+ Breast Cancer

February 16th 2023

A brief review of prevalent clinical trials in the early-stage HR+ breast cancer paradigm and how they help to inform treatment decision-making.

EP. 5: HR+ Metastatic Breast Cancer: Molecular Profiling and 1L Treatment Approaches

February 23rd 2023

Shifting their focus to HR+ metastatic disease, expert panelists consider the importance of molecular profiling and first-line treatment options.

EP. 6: Factors in Selecting 1L Therapy for Patients With HR+ Metastatic Breast Cancer

February 23rd 2023

Expert perspectives on factors that aid in the selection of optimal first-line therapy for patients with HR+ metastatic breast cancer.

EP. 7: Molecular Testing in Relapsed/Refractory HR+ Metastatic Breast Cancer

March 2nd 2023

A brief review of the role molecular profiling plays at a patient’s relapse with HR+ metastatic breast cancer.

EP. 8: Continuing CDK4/6 Inhibition at Progression of HR+ Metastatic Breast Cancer

March 2nd 2023

Key opinion leaders consider when it is appropriate to continue CDK4/6 inhibition at progression of disease in the setting of HR+ metastatic breast cancer.

EP. 9: HR+ Metastatic Breast Cancer: Optimal Selection of Endocrine Partners

March 9th 2023

Shared insight on the selection of endocrine partners while managing patients in the relapsed/refractory setting of HR+ metastatic breast cancer.

EP. 10: Other Treatment Modalities for HR+ Metastatic Breast Cancer

March 9th 2023

Comprehensive discussion on novel treatment modalities in HR+ metastatic breast cancer and insight to when it is appropriate to select these agents.

EP. 11: Evolution in the Field of HR+ Breast Cancer Management

March 16th 2023

Closing out their discussion on HR+ breast cancer management, expert panelists share their excitement for the evolving treatment paradigm.